ライフサイエンスコーパス: NMS

1 NMS were rated using the Movement Disorder Society Unifi

2 NMS-P118 proved to be a potent, orally available, and hi

3 Human MPNST cell lines (Mash-1, YST-1, NMS-2 and NMS-2PC cells) similarly coexpress multiple NR

4 constants of 30minus sign100 nM for the M(2) NMS-liganded and unliganded receptor, respectively.

5 es in the submillimolar range, inhibited [3H]NMS dissociation, and showed various patterns of positiv

6 holine (ACh) 3- to 5-fold for inhibiting [3H]NMS binding to M4 receptors but has no effect on ACh aff

7 In contrast, it inhibits [3H]NMS dissociation from M1 to M4 receptors at submillimola

8 effects of THRX-160209 on retardation of [3H]NMS dissociation were competitively inhibited by obidoxi

9 m binding of l-[3H]N-methyl scopolamine ([3H]NMS) to the five human muscarinic receptor subtypes (M1-

10 neutral, and negative cooperativity with [3H]NMS and acetylcholine, but there was no predictive relat

11 approximately neutral cooperativity with [3H]NMS at M1 to M4 and possibly M5 receptors.

12 ) was determined by the displacement of [3H]-NMS binding using membranes from transfected Chinese ham

13 715 and compared the binding modes of Cpd-5, NMS-P715, and reversine.

14 Comparison between unfolding of an NMS construct and that of truncated G-quadruplex constru

15 Using an NMS-iCre driver line, we confirmed that a subset of VTA

16 n MPNST cell lines (Mash-1, YST-1, NMS-2 and NMS-2PC cells) similarly coexpress multiple NRG-1 isofor

17 f the Mps1 kinase mutants bound to Cpd-5 and NMS-P715 and compared the binding modes of Cpd-5, NMS-P7

18 Individually, CSS and NMS have no effect.

19 ed motif, GAAG/CTTC, present in both CSS and NMS, is responsible for repression as the mutation in th

20 recombinant plasmids indicated that CSS- and NMS-mediated repression of transcription is position- an

21 The HMS and NMS groups did not differ with respect to baseline demog

22 four p97 inhibitors (DBeQ, ML240, ML241, and NMS-873) have differential responses to Walker A and B m

23 We also showed that MSN and NMS were portable across Type I, II and V CRISPR systems

24 que produced microvasculature parameters and NMS regions less impacted by the arterial-input-function

25 rom the action of the orthosteric antagonist NMS.

26 ed resistance to the MPS1 inhibitors AZ3146, NMS-P715, and CCT251455, identifying five point mutation

27 n the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), high

28 We found that HI activity was enhanced by NMS depending on the Ab's fine specificity (antigenic re

29 oxo-2,3-dihydro-1H-isoind ole-4-carboxamide (NMS-P118, 20by).

30 resistance to two closely related compounds, NMS-P715 and its derivative Cpd-5, but not to the well c

31 In contrast, NMS of the ventral tegmental area/substantia nigra (VTA/

32 Further, as proofs of concept, we used dCas9-NMS to efficiently reprogram human fibroblasts into indu

33 diction, as only one of the markers displays NMS (one-sided events).

34 PD with stable motor disease and disturbing NMS defined by a score of >=4 points on the Movement Dis

35 abilone for patients with PD with disturbing NMS, which appears to be driven by positive effects on a

36 nfirmed that a subset of VTA neurons express NMS and that chemogenetic modulation of VTA NMS neuron a

37 xpressing (VIP(+)), neuromedin S-expressing (NMS(+)) and gastrin-releasing peptide-expressing (GRP(+)

38 les from literature were simulated in the FE NMS model to verify effective integration of the softwar

39 in response to seasonality and the role for NMS neurons in adjusting hypothalamic function to day le

40 with PD are treated with antidepressants for NMSs, and the effect of the combination of PD medication

41 Further, NMS-Vgat deletion impairs intrinsic clock gene rhythms i

42 [(3)H]NMS ([(3)H]N-methylscopolamine) binding experiments conf

43 m2-Toxin fully blocked the binding of [(3)H]NMS and [(3)H]oxotremorine-M to M2 receptors with Hill c

44 Experimental data on [(3)H]NMS and [(3)H]QNB association and dissociation perfectly

45 egative, or neutral cooperativity with [(3)H]NMS and ACh, depending on the receptor subtype and natur

46 n the membranes were preincubated with [(3)H]NMS and then exposed to benzilylcholine mustard (covalen

47 amine failed to fully inhibit specific [(3)H]NMS binding in a manner that was quantitatively describe

48 t brain showed that m2-toxin decreased [(3)H]NMS binding in regions rich in M2 receptors and increase

49 ity to inhibit or modulate orthosteric [(3)H]NMS binding revealed that para-LRB-AC42 shared several p

50 ass: 7471 Da; irreversible blockade of [(3)H]NMS binding to cloned M(1) receptors at 25 degrees C; no

51 ed the nature of [(3)H]pirenzepine and [(3)H]NMS binding to human cortex and showed total [(3)H]piren

52 n M4 receptors, but slightly increased [(3)H]NMS binding to M1 receptors, an allosteric effect.

53 Surprisingly, there was no change in [(3)H]NMS binding to the cortex from this subset or those with

54 Zn(2+), acetylcholine displacement of [(3)H]NMS binding was enhanced by Mg(2+) and Zn(2+), acetylcho

55 and showed total [(3)H]pirenzepine and [(3)H]NMS binding was reduced by Zn(2+), acetylcholine displac

56 M(2)-M(5) receptors; 6-fold slowing of [(3)H]NMS dissociation at 37 degrees C).

57 ine significantly retarded the rate of [(3)H]NMS dissociation from CHO-hM(1) cell membranes, conclusi

58 n PG987 and other allosteric agents on [(3)H]NMS dissociation from M(3) receptors indicate that PG987

59 IN 62,577 and WIN 51,708 do not affect [(3)H]NMS dissociation from M(3) receptors.

60 (covalently binding specific ligand), [(3)H]NMS dissociation was blocked in wild-type receptors, but

61 87), has the unique effect of speeding [(3)H]NMS dissociation; its largest effect, 2.5-fold, is at M(

62 Dissociation kinetic studies using [(3)H]NMS further support that LY2119620 binds allosterically

63 ed 77% of the binding sites for 0.1 nM [(3)H]NMS in the rat brainstem (K(i) = 11 nM).

64 alogs with [(3)H]N-methyl scopolamine ([(3)H]NMS) and unlabeled acetylcholine (ACh) at M(1)-M(4) musc

65 obtained in [(3)H]N-methylscopolamine ([(3)H]NMS) binding studies, in that both AC-42 and the prototy

66 to inhibit [(3)H]N-methylscopolamine ([(3)H]NMS) binding to M1, left-shifting the ACh Ki approximate

67 ociation of [(3)H]N-methylscopolamine ([(3)H]NMS) from these receptors.

68 ations with N-[(3)H]methylscopolamine ([(3)H]NMS) or R(-)-[(3)H]quinuclidinyl benzilate ([(3)H]QNB),

69 binding of [(3)H]N-methylscopolamine ([(3)H]NMS) to cloned M2 receptors.

70 ced by Zn(2+), whereas BQCA effects on [(3)H]NMS, but not [(3)H]pirenzepine, binding was enhanced by

71 substantially more binding sites than [(3)H]NMS.

72 , chronic cocaine exposure may induce higher NMS intensity, suggesting neurotoxic effects on the LC.

73 The capture efficiency of the immune NMS reached 83 %, and the detection limit of this colori

74 undergoing the most significant increase in NMS cell proportion.

75 Longitudinal increase in NMS severity was associated with the older age (0.008) a

76 iation of a greater longitudinal increase in NMS with lower baseline Abeta1-42 level is an important

77 We evaluated the change in NMSs in patients taking an antidepressant and rasagiline

78 t a role for dopamine-enhancing therapies in NMSs in early PD and encourage further study and confirm

79 Compared to NU, CU demonstrated higher LC NMS for all probabilistic thresholds defined of 50-90% o

80 hildhood PICU survivors, 14.03% did not meet NMSs in the standardized primary school assessment.

81 ues of brucine with [3H]N-methylscopolamine (NMS) and unlabeled acetylcholine at m1-m5 muscarinic rec

82 line and the antagonist N-methylscopolamine (NMS) at M(1)minus signM(4) receptors have been analyzed

83 nyl benzilate (QNB) and N-methylscopolamine (NMS) bind to the binding pocket of the muscarinic acetyl

84 adiolabeled antagonists N-methylscopolamine (NMS) in the presence of methoctramine and its precursors

85 nce of noninactivated serum from naive mice (NMS).

86 s Microstent (HMS) and 187 to no microstent (NMS).

87 ersus cataract surgery alone (no microstent [NMS]).

88 t multipartite transactivation modules (MSN, NMS and eN3x9) and to build the CRISPR-dCas9 recruited e

89 Neuromusculoskeletal (NMS) models can aid in studying the impacts of the nervo

90 % in 77.3% of HMS group eyes and in 57.8% of NMS group eyes (difference = 19.5%, 95% confidence inter

91 The affinity of NMS at the allosteric site is in the micromolar range fo

92 amino acids to alanine decreased affinity of NMS for the allosteric binding site confirming results o

93 r loop are involved in allosteric binding of NMS.

94 ombinations, does not increase the degree of NMS for stimulus shape with other task variables.

95 ctramine physically prevents dissociation of NMS from the orthosteric binding site.

96 binding site on the extracellular domain of NMS-occupied M(2) receptors by interacting primarily wit

97 This highlights the importance of NMS for DBS outcomes assessments.

98 Understanding of interactions of NMS at the allosteric binding site is essential for corr

99 Chronic manipulation of NMS neurons is sufficient to induce neurotransmitter swi

100 /Trp(604) and the trifluoromethoxy moiety of NMS-P715, the methoxy moiety of Cpd-5, and complete abse

101 GF recapitulates the intestinal phenotype of NMS mice in vivo and in mouse intestinal organoids in vi

102 The allosteric binding site of NMS overlaps with the binding site of some allosteric, e

103 This study of NMS in early PD identified clinical and biological varia

104 ug may be a useful agent in the treatment of NMS.

105 ociated with reduced worsening of a range of NMSs in preliminary analyses.

106 vidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with qua

107 eptors, but reversibly and without effect on NMS dissociation.

108 ine neurotransmission and antidepressants on NMSs has not been studied.

109 ow that high concentrations of either QNB or NMS slow down dissociation of their radiolabeled species

110 In this study, we present a predictive NMS model that uses an embedded neural architecture with

111 The combined capability of a predictive NMS model within a FE framework can aid in improving our

112 e the performance of the K-SOM probabilistic-NMS (PNMS) technique against the NMS technique.

113 iously characterized patients with recurrent NMS (five females and three males; 34+/-2 yr) were recru

114 be better tolerated than the closely related NMS-P715.

115 s 2 and 3, respectively) to their respective NMS regions.

116 Here, we show in mice that neuromedin S (NMS) and vasoactive intestinal polypeptide (VIP) neurons

117 expression of the neuropeptide neuromedin S (NMS) is robustly increased in VTA DA neurons by morphine

118 ns expressing the neuropeptide neuromedin S (NMS) plays an essential role in the generation of daily

119 esicular transporter Vgat from neuromedin-S (NMS)(+) neurons-a subset of neurons critical for SCN fun

120 n the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization,

121 ed dissociation of [3H]N-methyl scopolamine (NMS).

122 is named as native mechanical segmentation (NMS).

123 be detectable as non-Mendelian segregations (NMS).

124 This nested model selection (NMS) assumes that the observed time-trace of contrast-ag

125 omenon known as nonlinear mixed selectivity (NMS).

126 In rodents, neonatal maternal separation (NMS) induces bowel dysfunctions that resemble IBS.

127 d a downstream negative modulatory sequence (NMS), which function in concert with each other, are req

128 ence of purified IgM and normal mouse serum (NMS), but not serum from Rag-2(-/-) mice, implicating a

129 or symptoms are globally present with severe NMS burden impacting quality of life in PD, there appear

130 The nickel mesh sheet (NMS) modified with capture antibodies was employed for c

131 he LC and quantified LC neuromelanin signal (NMS) intensity in 44 current cocaine users (CU; 37 men)

132 o unliganded M(1) receptors but did not slow NMS dissociation.

133 evement below the National Minimum Standard (NMS) in year 3 of primary school.

134 customized the loss and non-max suppression (NMS) functions.

135 ongitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients w

136 g evidence suggests that non-motor symptoms (NMS) in Parkinson's disease (PD) have differential progr

137 ogue, as a treatment for non-motor symptoms (NMS) in Parkinson's disease (PD).

138 of life (QoL), motor and non-motor symptoms (NMS).

139 ive impairment, and other nonmotor symptoms (NMSs) are common early in Parkinson disease (PD) and may

140 nts with presumed neurally mediated syncope (NMS) and documented asystole but syncope still recurred

141 at Paxil prevents neurally mediated syncope (NMS) by attenuating the sympathoinhibition and vagotonia

142 he development of neurally mediated syncope (NMS) by manipulating overall sympathetic outflow in subj

143 vious studies, we did not find evidence that NMS is predictive of task performance.

144 It has previously been hypothesized that NMS emerges as a result of training to perform tasks in

145 recording of calcium dynamics revealed that NMS neurons alter PVN network activity in response to wi

146 Here we show that NMS induces expansion of intestinal stem cells (ISCs) an

147 Together, our current data suggest that NMS-expressing neurons represent a novel subset of VTA n

148 obabilistic-NMS (PNMS) technique against the NMS technique.

149 ubjects completed the study, whereas all the NMS patients developed syncope.

150 n three out of eight controls and in all the NMS patients.

151 group and from 1.7+/-0.9 to 0.7+/-0.9 in the NMS group (difference = -0.4 medications; P < 0.001).

152 in the HMS group and -5.3+/-3.9 mmHg in the NMS group (difference = -2.3 mmHg; 95% CI, -3.0 to -1.6;

153 mHg was significantly higher at 14.4% in the NMS group compared with 1.4% in the HMS group (P < 0.001

154 on POD1 was also significantly higher in the NMS group than in the HMS group (22.5% vs. 3.0%, P < 0.0

155 IOP in the NMS group was significantly higher than in the HMS group

156 ); 14.03% of PICU survivors did not meet the NMS compared with 8.96% of matched controls (p < 0.001).

157 ciated with a higher risk of not meeting the NMS.

158 After baseline stratification based on the NMS Scale, Hoehn and Yahr Scale and levodopa response as

159 The NMSs were assessed by Movement Disorder Society-sponsore

160 es of animals' brain voxels along with their NMS results were used to build a K-SOM (topology-size: 8

161 surgery-like precisions, we anticipate this NMS approach offers unprecedented perspective to deciphe

162 ndependent of the concentration of unlabeled NMS or QNB added to reveal dissociation.

163 acokinetic (PK) analysis was performed using NMS to estimate three model regions: Model-1: normal vas

164 (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years.

165 Whole-cell recordings from VIP(+), NMS(+), and GRP(+) neurons in acute SCN slices revealed

166 r specific to morphine, as modulation of VTA NMS activity did not affect cocaine behaviors, consisten

167 NMS and that chemogenetic modulation of VTA NMS neuron activity altered morphine responses in male a

168 highlighting the functional relevance of VTA NMS-expressing neurons.

169 Specifically, VTA NMS neuronal activation promoted morphine locomotor acti

170 ompounds exhibit positive cooperativity with NMS, particularly at M(2) and M(4) receptors.

171 crease in the proportion of PFC neurons with NMS exclusively for spatial working memory, but not for

172 ncement of sympathetic tone in patients with NMS improves orthostatic tolerance and raises the possib